Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Mologni, Luca ^a   Brussolo, Stefania ^b   Ceccon, Monica ^a   Gambacorti Passerini, Carlo ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b CA' FOSCARI UNIVERSITY OF VENICE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BETA CATENIN; HERMES ANTIGEN; K RAS PROTEIN; MYC PROTEIN; PKF 115 584; PYRVINIUM EMBONATE; SALIRASIB; SURVIVIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL DEATH; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG SYNERGISM; FARNESOL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; PERYLENE; PROTO-ONCOGENE PROTEINS; PYRVINIUM COMPOUNDS; RAS PROTEINS; SALICYLATES; WNT PROTEINS;

EID: 84870846269     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051449     Document Type: Article

References (63)

1. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, et al. (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346: 645-652.
2. Oxnard GR, Miller VA, (2010) Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. Oncology (Williston Park) 24: 392-399.
3. Sharma SV, Settleman J, (2007) Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 21: 3214-3231.
4. Frattini M, Balestra D, Suardi S, Oggionni M, Alberici P, et al. (2004) Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res 10: 4015-4021.
5. Markowitz SD, Bertagnolli MM, (2009) Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 361: 2449-2460.
6. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318: 1108-1113.
7. Kucherlapati R (2012) Integrative analysis examples from TCGA tumor projects. AACR Annual Meeting.
8. Gerstung M, Eriksson N, Lin J, Vogelstein B, Beerenwinkel N, (2011) The temporal order of genetic and pathway alterations in tumorigenesis. PLoS One 6: e27136.
9. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, et al. (2002) The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111: 241-250.
10. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB, (2003) Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 9: 1291-1300.
11. Mariadason JM, Bordonaro M, Aslam F, Shi L, Kuraguchi M, et al. (2001) Down-regulation of beta-catenin TCF signaling is linked to colonic epithelial cell differentiation. Cancer Res 61: 3465-3471.
12. Fabien N, Paulin C, Santoro M, Berger N, Grieco M, et al. (1992) Detection of RET oncogene activation in human papillary thyroid carcinomas by in situ hybridisation. Br J Cancer 66: 1094-1098.
13. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274.
14. Vasovcak P, Pavlikova K, Sedlacek Z, Skapa P, Kouda M, et al. (2011) Molecular genetic analysis of 103 sporadic colorectal tumours in Czech patients. PLoS One 6: e24114.
15. Ahlquist T, Bottillo I, Danielsen SA, Meling GI, Rognum TO, et al. (2008) RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A. Neoplasia 10: 680-686, 682 p following 686.
16. The Cancer Genome Atlas Network, (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337.
17. Janssen KP, Alberici P, Fsihi H, Gaspar C, Breukel C, et al. (2006) APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology 131: 1096-1109.
18. Sansom OJ, Meniel V, Wilkins JA, Cole AM, Oien KA, et al. (2006) Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc Natl Acad Sci U S A 103: 14122-14127.
19. Mologni L, Dekhil H, Ceccon M, Purgante S, Lan C, et al. (2010) Colorectal Tumors Are Effectively Eradicated by Combined Inhibition of {beta}-Catenin, KRAS, and the Oncogenic Transcription Factor ITF2. Cancer Res 70: 7253-7263.
20. Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, et al. (2007) Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci U S A 104: 7516-7521.
21. Gandhirajan RK, Staib PA, Minke K, Gehrke I, Plickert G, et al. (2010) Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Neoplasia 12: 326-335.
22. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, et al. (2004) Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 5: 91-102.
23. Doghman M, Cazareth J, Lalli E, (2008) The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. J Clin Endocrinol Metab 93: 3222-3225.
24. Downey AS, Chong CR, Graczyk TK, Sullivan DJ, (2008) Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model. Antimicrob Agents Chemother 52: 3106-3112.
25. Thorne CA, Hanson AJ, Schneider J, Tahinci E, Orton D, et al. (2010) Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat Chem Biol 6: 829-836.
26. Marciano D, Ben-Baruch G, Marom M, Egozi Y, Haklai R, et al. (1995) Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth. J Med Chem 38: 1267-1272.
27. Haklai R, Elad-Sfadia G, Egozi Y, Kloog Y, (2008) Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemother Pharmacol 61: 89-96.
28. Zundelevich A, Elad-Sfadia G, Haklai R, Kloog Y, (2007) Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid). Mol Cancer Ther 6: 1765-1773.
29. Rotblat B, Ehrlich M, Haklai R, Kloog Y, (2008) The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods Enzymol 439: 467-489.
30. Yang M, Zhong WW, Srivastava N, Slavin A, Yang J, et al. (2005) G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway. Proc Natl Acad Sci U S A 102: 6027-6032.
31. Ilyas M, Tomlinson IP, Rowan A, Pignatelli M, Bodmer WF, (1997) Beta-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci U S A 94: 10330-10334.
32. Kohler EM, Chandra SH, Behrens J, Schneikert J, (2009) Beta-catenin degradation mediated by the CID domain of APC provides a model for the selection of APC mutations in colorectal, desmoid and duodenal tumours. Hum Mol Genet 18: 213-226.
33. Smakman N, van den Wollenberg DJ, Elias SG, Sasazuki T, Shirasawa S, et al. (2006) KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 66: 5403-5408.
34. Gayet J, Zhou XP, Duval A, Rolland S, Hoang JM, et al. (2001) Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene 20: 5025-5032.
35. Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, et al. (2010) Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 70: 5901-5911.
36. Tan YH, Liu Y, Eu KW, Ang PW, Li WQ, et al. (2008) Detection of BRAF V600E mutation by pyrosequencing. Pathology 40: 295-298.
37. Mologni L, Cleris L, Magistroni V, Piazza R, Boschelli F, et al. (2009) Valproic acid enhances bosutinib cytotoxicity in colon cancer cells. Int J Cancer 124: 1990-1996.
38. Elad G, Paz A, Haklai R, Marciano D, Cox A, et al. (1999) Targeting of K-Ras 4B by S-trans, trans-farnesyl thiosalicylic acid. Biochim Biophys Acta 1452: 228-242.
39. Weisz B, Giehl K, Gana-Weisz M, Egozi Y, Ben-Baruch G, et al. (1999) A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene 18: 2579-2588.
40. Levy R, Grafi-Cohen M, Kraiem Z, Kloog Y, (2010) Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas. Mol Cancer Ther 9: 2208-2219.
41. Chou TC, (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681.
42. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, et al. (1998) Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512.
43. Sears R, Leone G, DeGregori J, Nevins JR, (1999) Ras enhances Myc protein stability. Mol Cell 3: 169-179.
44. Zhang T, Otevrel T, Gao Z, Ehrlich SM, Fields JZ, et al. (2001) Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 61: 8664-8667.
45. Kaneko R, Tsuji N, Asanuma K, Tanabe H, Kobayashi D, et al. (2007) Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer. J Biol Chem 282: 19273-19281.
46. Sarthy AV, Morgan-Lappe SE, Zakula D, Vernetti L, Schurdak M, et al. (2007) Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells. Mol Cancer Ther 6: 269-276.
47. Smith TC, Kinkel AW, Gryczko CM, Goulet JR, (1976) Absorption of pyrvinium pamoate. Clin Pharmacol Ther 19: 802-806.
48. Esumi H, Lu J, Kurashima Y, Hanaoka T, (2004) Antitumor activity of pyrvinium pamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methyl-qu inolinium pamoate salt, showing preferential cytotoxicity during glucose starvation. Cancer Sci 95: 685-690.
49. Yu DH, Macdonald J, Liu G, Lee AS, Ly M, et al. (2008) Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy. PLoS One 3: e3951.
50. Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, et al. (2010) Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A 107: 18545-18550.
51. Biankin AV, Hudson TJ, (2011) Somatic variation and cancer: therapies lost in the mix. Hum Genet 130: 79-91.
52. Friday BB, Adjei AA, (2005) K-ras as a target for cancer therapy. Biochim Biophys Acta 1756: 127-144.
53. Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, et al. (2012) Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas. Clin Cancer Res 2012: 12.
54. Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, et al. (2011) Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest 121: 4311-4321.
55. Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ, (2009) Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer 125: 2332-2341.
56. Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, et al. (2009) Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137: 821-834.
57. Singh A, Sweeney MF, Yu M, Burger A, Greninger P, et al. (2012) TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 148: 639-650.
58. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, et al. (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137: 835-848.
59. Feig LA, (2003) Ral-GTPases: approaching their 15 minutes of fame. Trends Cell Biol 13: 419-425.
60. Misra S, Obeid LM, Hannun YA, Minamisawa S, Berger FG, et al. (2008) Hyaluronan constitutively regulates activation of COX-2-mediated cell survival activity in intestinal epithelial and colon carcinoma cells. J Biol Chem 283: 14335-14344.
61. Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS,et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J 278: 1429-1443.
62. Gorospe M, Wang X, Guyton KZ, Holbrook NJ, (1996) Protective role of p21(Waf1/Cip1) against prostaglandin A2-mediated apoptosis of human colorectal carcinoma cells. Mol Cell Biol 16: 6654-6660.
63. Poluha W, Poluha DK, Chang B, Crosbie NE, Schonhoff CM, et al. (1996) The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells. Mol Cell Biol 16: 1335-1341.